Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.34 |
| ▸ | AGXT | P21549 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075039 | 0.81 | LMNA (0.31) | ALDH1A1LMNAMAOBMEN1HTT | |
| SCHEMBL3744881 | 0.77 | LMNA (0.43) | ALDH1A1LMNAMAOBMEN1HTT | |
| SCHEMBL4381803 | 0.76 | IDO1 (0.42) | IDO1AGXTCYP3A4ALDH1A1KCNH2 | |
| SCHEMBL4344143 | 0.75 | ASIC3 (0.46) | IDO1ALDH1A1MEN1KMT2AKCNH2 | |
| SCHEMBL16588053 | 0.75 | KCNH2 (0.36) | IDO1AGXTCYP3A4KCNH2 | |
| SCHEMBL2385207 | 0.72 | KDM4E (0.57) | ALDH1A1LMNAHTTKCNH2MAPT | |
| SCHEMBL5013990 | 0.72 | HIF1A (0.36) | ALDH1A1LMNAMEN1HTTKMT2A | |
| SCHEMBL5013989 | 0.70 | KCNH2 (0.39) | IDO1AGXTLMNAHTTKCNH2 | |
| SCHEMBL5014468 | 0.70 | NPSR1 (0.34) | IDO1AGXTCYP3A4ALDH1A1LMNA | |
| SCHEMBL3749596 | 0.69 | CCR1 (0.61) | LMNAMAOBMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | IDO1 1074/4885AGXT 1676/4885CYP3A4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.